In a significant development that is expected to change the IT landscape <br />of Andhra Pradesh, IT Minister Nara Lokesh today signed a Memorandum of Understanding (MoU) with the ANSR, a global ...

The luxury cruise liner M.V. Empress arrived at the Visakhapatnam International Cruise Terminal here today, marking a significant milestone in the city’s advent as a premier destination for Cruise ...

HSBC has cut the target price on Biocon Ltd. from Rs 400 to Rs 390, as it sees negative impact on earnings per share due to the company's Rs 4,500-crore qualified institutional placement that happened ...

Biocon share price jumped over 4% on Tuesday after the company announced that its subsidiary has secured market entry date for Yesafili, an interchangeable biosimilar to Eylea, in the US. Biocon ...

Biocon also got an Establishment Inspection Report (EIR) from the US FDA for their greenfield API facility (Site 6) in Visakhapatnam, Andhra Pradesh.

Biocon receives FDA report, can start supplies to US from Vizag facility With this approval, Biocon is authorised to begin commercial supplies from this greenfield active pharmaceutical ingredient ...

Biocon Q1 Net Profit: Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited revealed that having successfully integrated the acquired business last year, Biocon Biologics’ focus in ...

Bangalore: Biocon has announced that the Company has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (USFDA), for API ...

Biocon gets 4 observations from USFDA for Andhra Pradesh facility The US Food and Drug Administration (USFDA) concluded a GMP inspection of the company's API facility (Site 5), located at ...

Bangalore: Biocon has informed in a BSE filing that the U.S. Food and Drug Administration (USFDA) has concluded a GMP inspection with three observations at the Company's API facility (Site 6), at ...

In a filing to the stock exchange, Biocon stated, "The U.S. Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 6), located at Visakhapatnam, Andhra Pradesh ...